纳米催化剂具有自强化级联反应,用于增强癌症治疗
Xuewen Zhang1, Yannan Wu1, Bing Wang2
1Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, Fujian 361102, China.
ACS applied materials & interfaces
|June 27, 2025
概括
这项研究引入了一个新的纳米催化剂平台,CIGP,用于增强癌症治疗. 通过重塑瘤微环境,CIGP有效地产生反应性氧物种,并利用光热疗法抑制瘤生长.
科学领域:
- 生物医学工程 生物医学工程
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
背景情况:
- 硫化铜纳米催化剂在瘤治疗中表现有前途,但由于瘤的微环境,催化效率受到限制.
- 开发具有广泛能量波段和高氧化/还原能力的纳米催化剂对于有效的癌症治疗至关重要.
研究的目的:
- 为增强瘤治疗构建基于异构连接 (HJ) 的纳米光触媒平台 (Cu7S4-In2S3@GOx@PEG,CIGP).
- 提高催化效率,克服现有的硫化铜基癌症疗法的局限性.
主要方法:
- 用葡萄糖氧化酶 (GOx) 和聚乙烯糖醇修改的Cu7S4-In2S3异构连接的制造.
- 评估CIGP的光触发反应性氧物种 (ROS) 产生,以应对氧和过氧化.
- 评估GOx在调节瘤微环境pH和氧化还原平衡中的作用.
- 对CIGP在空间时间可控光热疗法中对瘤细胞在辐射下有效性的研究.
主要成果:
- 在CIGP中的Cu7S4-In2S3 HJs改善了光生成的电子孔分离,增强了ROS生成.
- GOx成功催化了葡萄糖的转化,产生H2O2并改变TME的pH以有利于ROS积累.
- CIGP通过照热疗法在辐射下有效抑制瘤细胞生长.
结论:
- CIGP提供了一个创新的平台,用于重塑瘤微环境的酸度.
- 开发的纳米催化剂通过联合光动力学和光热疗法协同增强抗瘤反应.
- 这种方法在推进基于纳米催化剂的癌症治疗方面具有重大潜力.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Electron Transport Chain: Complex I and II
15.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.1K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Amplifying Signals via Enzymatic Cascade
9.3K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
9.3K


